{
    "name": "selenium",
    "comment": "OTC",
    "other_names": [
        "Selepen"
    ],
    "classes": [
        "Trace Elements/Metals"
    ],
    "source": "https://reference.medscape.com/drug/selepen-selenium-344443",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Excreted in breast milk; use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excreted in breast milk; use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Undiluted injection into peripheral vein"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "selenium will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "selenium decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alendronate",
            "description": {
                "common": "selenium will decrease the level or effect of alendronate by  cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or 30 min after alendronate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bictegravir",
            "description": {
                "common": "selenium will decrease the level or effect of bictegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer bictegravir on an empty stomach at least 2 h before or 6 h after polyvalent cation containing drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferiprone",
            "description": {
                "common": "selenium will decrease the level or effect of deferiprone by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate deferiprone administration from ingestion of polyvalent cations by at least 4 h."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolutegravir",
            "description": {
                "common": "selenium will decrease the level or effect of dolutegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer dolutegravir at least 2 h before or 6 h after polyvalent cations. Administer the dolutegravir/rilpivirine combination at least 4 h before or 6 h after polyvalent cations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "selenium will decrease the level or effect of eltrombopag by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate eltrombopag administration from polyvalent cations by at least 2 h."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etidronate",
            "description": {
                "common": "selenium will decrease the level or effect of etidronate by  cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or after etidronate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibandronate",
            "description": {
                "common": "selenium will decrease the level or effect of ibandronate by  cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or 1 h after ibandronate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "selenium will decrease the level or effect of omadacycline by  cation binding in GI tract. Modify Therapy/Monitor Closely. Do not take polyvalent cations within 4 hr before or after omadacycline."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillamine",
            "description": {
                "common": "selenium will decrease the level or effect of penicillamine by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate penicillamine administration from ingestion of polyvalent cations by at least 1 h."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "raltegravir",
            "description": {
                "common": "selenium will decrease the level or effect of raltegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer raltegravir at least 2 h before or 6 h after polyvalent cations. Note: Dose separation may not adequately avoid this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risedronate",
            "description": {
                "common": "selenium will decrease the level or effect of risedronate by  cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or 30 min after risedronate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiludronate",
            "description": {
                "common": "selenium will decrease the level or effect of tiludronate by  cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or after tiludronate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trientine",
            "description": {
                "common": "selenium will decrease the level or effect of trientine by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer trientine at least 1 hr before or after polyvalent cations (2 hr if oral iron administered)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Irritability",
            "percent": null
        }
    ]
}